drugset / Trial / NCT03001453

Intraoperative Liposomal Bupivacaine vs. Bupivacaine for Total Hip Replacement Pain Management

NCT03001453 ↗

Phase 2 Completed 107 enrolled American Hip Institute
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to compare two medications currently injected intra-operatively to help decrease pain after surgery in patients undergoing a primary total hip replacement (THR). The two medications are Exparel® (bupivacaine liposome injectable suspension) plus bupivacaine with epinephrine versus bupivacaine with epinephrine. This study is looking to see if one medication works better than the other in managing post-operative pain after THR. The study hypothesis is that Exparel® plus bupivacaine with epinephrine will demonstrate better pain management in THR patients post-operatively. Both medications are FDA-approved for post-operative analgesia.

Timeline

Start
2014-04
Primary completion
2016-03
Completion
2016-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bupivacaine Other / unclassified 0.25 % Other
Comparator Bupivacaine Other / unclassified 40 ml Other
Comparator Bupivacaine Other / unclassified 60 ml Other
Comparator Bupivacaine Other / unclassified 266 mg Other

Indications